Taejoon Pharmaceutical Co., Ltd. clinical trials
The registry lists 16 studies whose lead sponsor is Taejoon Pharmaceutical Co., Ltd.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 9, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 16studies on the registry
- 1open to participants now
- 2phase 3 studies under way
- 1reach primary completion within a year
Get an email when these change. Save the Taejoon Pharmaceutical Co., Ltd. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
What it is testing
The drugs Taejoon Pharmaceutical Co., Ltd.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- polyethylene glycol 33501 in phase 30 open · 1
Coming up
1 of Taejoon Pharmaceutical Co., Ltd.’s studies under way reach primary completion within a year, all of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- 1AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
- Apr 2027Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With MyopiaPhase 3 · NCT07790640
Add it to your calendar (.ics) → With an account.
All 16 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 323
- 24
- 25
- 126
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Taejoon Pharmaceutical Co., Ltd..
- Taejoon Pharmaceutical Co., Ltd.16 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 16 of 16.
- Comparing Efficacy and Safety of CTO0303 in Pediatric SubjectsRecruitingNCT06609525Phase 2/3
- Evaluate the Safety and Efficacy of TJO-087Active, not recruitingNCT07810972Phase 2
- Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With MyopiaActive, not recruitingNCT07790640Phase 3
- Evaluate the Efficacy and Safety of CTO0307 in Adults With PresbyopiaCompletedNCT07723716Phase 3
- Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases PatientsCompletedNCT06427031Phase 3
- A Phase 3 Clinical Trials for Bowel Preparation for ColonoscopyCompletedNCT06287606Phase 3
- A Phase 3 Trial in Bowel Preparation for ColonoscopyCompletedNCT05870553Phase 3
- A Prospective, Randomized, Investigator-blinded, Parallel, Multi-center, Phase 3 TrialCompletedNCT05670470Phase 3
- Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease PatientsCompletedNCT04127851Phase 4
- Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease PatientsStatus unknownNCT05346783Phase 1/2
- A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy AdultsStatus unknownNCT05262179Phase 1
- Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease PatientsStatus unknownNCT05245604Phase 3
- Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.Status unknownNCT04164459Phase 4
- A Prospective, Randomized, Single-blinded (Evaluator), Parallel, Multi-center, Phase 3 Trial in Bowel Preparation for ColonoscopyCompletedNCT03544944Phase 3
- A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension PatientsCompletedNCT03419975Phase 3
- Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye SyndromesCompletedNCT02461719Phase 3